share_log

HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $1

HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $1

HC Wainwright & Co.维持对SAB Biotherapeutics的买入,将目标价下调至1美元
Benzinga ·  2023/11/14 13:46

HC Wainwright & Co. analyst Edward White maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $2 to $1.

HC Wainwright & Co. 分析师爱德华·怀特维持SAB Biotherapeutics(纳斯达克股票代码:SABS)的买入,并将目标股价从2美元下调至1美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发